The rise of Viagra initially drove a surge for major pharmaceutical companies, but recent developments present a complicated scenario for shareholders. Off-patent alternatives are eroding revenue, and persistent patent https://amieijcr262634.pages10.com/sildenafil-and-the-pharmaceutical-industry-a-volatile-investment-76596859